Zacks Investment Research Lowers Edap Tms (NASDAQ:EDAP) to Sell

Edap Tms (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, September 13th.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Several other analysts have also recently commented on the company. HC Wainwright restated a “buy” rating and issued a $6.50 price target on shares of Edap Tms in a report on Wednesday, May 16th. ValuEngine upgraded Edap Tms from a “hold” rating to a “buy” rating in a report on Monday, July 16th. Finally, TheStreet upgraded Edap Tms from a “d+” rating to a “c” rating in a report on Tuesday, June 26th.

EDAP stock traded down $0.05 during trading on Thursday, hitting $2.88. The stock had a trading volume of 32,488 shares, compared to its average volume of 249,802. Edap Tms has a 1-year low of $2.07 and a 1-year high of $4.25. The company has a market capitalization of $89.31 million, a price-to-earnings ratio of -288.00 and a beta of 0.53. The company has a current ratio of 2.41, a quick ratio of 1.97 and a debt-to-equity ratio of 0.07.

Edap Tms (NASDAQ:EDAP) last announced its earnings results on Wednesday, August 29th. The medical equipment provider reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The firm had revenue of $10.14 million during the quarter, compared to analyst estimates of $10.74 million. Edap Tms had a negative net margin of 3.55% and a negative return on equity of 2.66%. As a group, research analysts predict that Edap Tms will post -0.03 earnings per share for the current year.

A hedge fund recently raised its stake in Edap Tms stock. Archon Capital Management LLC lifted its position in shares of Edap Tms SA (NASDAQ:EDAP) by 7.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,019,011 shares of the medical equipment provider’s stock after purchasing an additional 71,336 shares during the quarter. Edap Tms comprises approximately 0.2% of Archon Capital Management LLC’s holdings, making the stock its 14th largest holding. Archon Capital Management LLC owned approximately 3.51% of Edap Tms worth $2,364,000 at the end of the most recent quarter. Institutional investors own 8.13% of the company’s stock.

About Edap Tms

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Further Reading: Investing in Growth Stocks

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply